Opinion|Videos|August 29, 2024
Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly share perspective/insights on emerging novel agents in R/R CLL: Bispecific antibodies
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5